Dyve Biosciences news

Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy and Safety Study of a Transdermal Alkalinizing and Pain Relieving Treatment for Acute Gout Pain

Objectives:

Gout is characterized by a build-up of monosodium urate (MSU) crystals in and around the joints. MSU crystal formation and dissolution is affected by pH. There are reports in the literature of the use of alkalizat

Dyve Biosciences received FDA clearance to begin a Phase 2 study of its DYV-700 transdermal therapeutic for the treatment of acute gout pain.

Thousand Oaks, Calif.-based Dyve said it plans to begin the Targets study in the first quarter of 2020. It is slated to be a double-blind, placebo-controlled, randomized clinical trial to evaluate the efficacy of DYV-700 in patients with acute gout flare.

The Targets trial is s